MRK · News · 20260824N
Keytruda Patent Expiration Outlook
Merck & Co., Inc. · 2026-08-24 · Importance 56 · Surprise 42 · In source text
Third-party reports continue to identify Keytruda’s upcoming loss of exclusivity as a competitive risk for Merck’s oncology franchise. One report specifies an impending 2028 patent expiration, which could increase exposure to follow-on competition after Keytruda’s exclusivity period. The risk is being weighed alongside positive Phase 3 results for Merck’s personalized cancer therapy and generally positive analyst sentiment.
Key facts
- Merck & Co., Inc.'s Keytruda has an expected patent expiration in 2028. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | probable | — | Merck & Co., Inc.'s Keytruda has an expected patent expiration in 2028. |